5037-60-5

Usage

Uses

Used in Pharmaceutical Industry:
4,7-dimethyl-2,3-dihydroinden-1-one is used as a precursor in the manufacturing of various pharmaceuticals for its ability to serve as a building block in the synthesis of complex organic molecules, contributing to the development of new drugs.
Used in Agrochemical Industry:
4,7-dimethyl-2,3-dihydroinden-1-one is used as a precursor in the production of agrochemicals, leveraging its role in organic synthesis to create compounds that can be utilized in agricultural applications.
Used in Fragrance Industry:
4,7-dimethyl-2,3-dihydroinden-1-one is used as a component in the production of fragrances, capitalizing on its strong, fruity odor to enhance the scent profiles of various perfumes and scented products.
Used in Flavoring Industry:
4,7-dimethyl-2,3-dihydroinden-1-one is used as a component in the creation of flavorings, employing its distinctive fruity taste to add depth and complexity to food and beverage products.

InChI:InChI=1/C11H12O/c1-7-3-4-8(2)11-9(7)5-6-10(11)12/h3-4H,5-6H2,1-2H3

Upstream product

• 106-42-3 para-xylene 
• 814-68-6 acryloyl chloride 
• 625-36-5 2-chloropropionyl chloride 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 859966-58-8 3-(2,5-dimethylphenyl)propanoic acid chloride 
• 6729-12-0 4,7-dimethyl-indan-1-one oxime 
• 824-45-3 2,5-dimethylbenzyl chloride 
• 7664-93-9 sulfuric acid 
• 22422-19-1 3-chloro-1-(2,5-dimethylphenyl)propan-1-one 
• 25173-75-5 3-(2,5-dimethylphenyl)propanoic acid 
• 142342-94-7 4,7-dimethyl-3-oxo-indan-1-carboxylic acid 

Downstream Products

• 24623-36-7 4,7-dimethyl-2-(hydroxyimino)-1-indanone 
• 1438276-16-4 C₂₇H₃₀OSi 
• 24634-05-7 3,6-Dimethyl-2-cyanomethyl-benzoylchlorid 
• 84944-42-3 3,6-dimethylhomophthalic acid 
• 6974-97-6 4,7-dimethyl-1H-indene 
• 943303-51-3 4,7-dimethyl-3-(phenylethynyl)-1H-indene 
• 6682-71-9 4,7-dimethylindane 
• 54889-59-7 4,8-dimethyl-3,5,6,7-tetrahydro-2H-s-indacen-1-one 

Relevant academic research and scientific papers

POLYMERIZATION CATALYSTS

Embodiments of the present disclosure directed towards polymerization catalysts having improved ethylene enchainment and/or improved catalyst productivity. As an example, the present disclosure provides a polymerization catalyst of Formula (I), wherein each of R1 to R12 is independently a C1 to C20 alkyl, aryl or aralkyl group, or a hydrogen, wherein at least one of R4 to R7 is not a hydrogen, wherein M is a Group 4 metal, and wherein, each X is independently a halide, C1 to C20 alkyl, aralkyl or hydrogen

CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST

The invention relates to a metallocene complex (1) according to formula (I) wherein M is a metal selected from lanthanides or transition metals from group 3, 4, 5 or 6 of the Periodic System of the Elements, Q is an anionic ligand to M, k is the number of Q groups and equals the valence of M minus 2, R is a bridging group containing at least one carbon atom bonded to the indenyl moiety at 2-position, R1, R2, R3 and R4 are each independently chosen from the group consisting of H, a halogen atom and a C1-C20 hydrocarbylgroup, and wherein at least one of R1 and R2 is not H, and at least one of R3 and R4 is not H. The invention also relates to a catalyst comprising the metallocene complex, to a process for making polyolefins and to the use of the polyolefins for making articles.

Ruthenium Trichloride Catalyzed Highly Efficient Deoximation of Oximes to the Carbonyl Compounds and Nitriles without Acceptors

An acceptor-free catalysis protocol for the deoximation of ketoximes and aldoximes using RuCl3 as the catalyst has been developed. Under the optimized conditions, various oximes were converted to ketones and nitriles with excellent isolated yields. An acceptor-free catalysis protocol for the deoximation of ketoximes and aldoximes using RuCl3 as the catalyst has been developed. Under the optimized conditions, various oximes were converted to ketones and nitriles with excellent isolated yields.

Tuning the rotation rate of light-driven molecular motors

Overcrowded alkenes are among the most promising artificial molecular motors because of their ability to undergo repetitive light-driven unidirectional rotary motion around the central C=C bond. The exceptional features of these molecules render them highly useful for a number of applications in nanotechnology. Many of these applications, however, would benefit from higher rotation rates. To this end, a new molecular motor was designed, and the isomerization processes were studied in detail. The new motor comprises a fluorene lower half and a five-membered-ring upper half; the upper-half ring is fused to a p-xylyl moiety and bears a tert-butyl group at the stereogenic center. The kinetics of the thermal isomerization was studied by low-temperature UV-vis spectroscopy as well as by transient absorption spectroscopy at room temperature. These studies revealed that the tert-butyl and p-xylyl groups in the five-membered-ring upper half may be introduced simultaneously in the molecular design to achieve an acceleration of the rotation rate of the molecular motor that is larger than the acceleration obtained by using either one of the two groups individually. Furthermore, the new molecular motor retains unidirectional rotation while showing remarkably high photostationary states.

Synthesis of 7-substituted derivatives of 5, 8-dimethylisoquinoline

7-Bromo-5,8-dimethylisoquinoline was selectively synthesized by the bromination of 5,8-dimethylisoquinoline obtained in five steps from p-xylene as a starting material. Further,7-bromo-5,8-dimethylisoquinolinegave 7-amino-5,8-dimethylisoquinoline by the reaction with ammonia and various 7-anilino-5,8-dimethylisoquinolines via a palladium-catalyzed coupling reaction with anilines.

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

Electron-transfer-induced tautomerization in methylindanones: Electronic control of the tunneling rate for enolization

The radical cations generated from 4-methyl- and 4,7-dimethylindanone, as well as their deuterated isotopomers, isolated in Argon matrices, were found to undergo enolization to the corresponding enol radical cations at rates that differ by orders of magnitude. It is shown by quantum chemical calculations that the effect of the remote methyl group in the 4-position is of purely electronic nature in that it stabilizes the unreactive π-radical relative to the reactive σ-radical state of the 7-methylindanone radical cation. The observed kinetic behavior of the two compounds can be reproduced satisfactorily on the basis of calculated heigth and width of the thermal barrier for enolization, using the Bell model for quantum mechanical tunneling. High-level calculations on the methylacrolein radical cation show that barriers for enolization in radical cations are overestimated by B3LYP/6-31G*.

Bridged metallocene complex for the (co) polymerization of olefins

A “bridged” bis-cyclopentadienyl complex which can be advantageously used for the formation of a catalytic system active in the (co)polymerization of ethylene and other a-olefins is represented by means of the following formula (II): wherein: M represents a metal selected from titanium, zirconium or hafnium; A′ and A″ each independently represent an anion containing an η5-cyclopentadienyl ring coordinated to M; or R″ each independently represents a group of an anionic nature a-bound to the metal M; B represents an unsaturated bivalent organic residue having from 1 to 30 carbon atoms bound, respectively, to the ring of group and to the -CH2- methylene group by means unsaturated carbon atoms. This complex, combined with a suitable cocata forms a catalyst with a high activity in the poization of olefins, producing polymers with molecular weight, especially in the case of the merization of ethylene with a second α-olefir.

Synthesis of substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: Evaluation of structure-activity relationships for cytotoxicity

New substituted indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides were prepared from methyl 2-amino-3-formylbenzoate by a new Friedlander synthesis. Evaluation of these carboxamides for cytotoxicity in a panel of cell lines showed that small lipophilic substituents in the non-carboxamide ring, in a pseudo-peri position to the side chain, significantly increased cytotoxic potency while retaining a pattern of cytotoxicity consistent with a non-topo II mode of action. The methyl-substituted indeno[1,2-b]quinoline-6-carboxamide demonstrated substantial effectiveness (20-day growth delays) in a sub-cutaneous colon 38 in vivo tumor model. This is comparable to that reported for the dual topo I/II inhibitor DACA that is in clinical trial. Copyright (C) 2000 Elsevier Science Ltd.